Proassurance Corp (PRA) Stock Analysis and Metrics

Proassurance

NYSE: PRA

$25.00 ▲ +0.00 (+0.00%)

At close: Jul 2, 2026 · 4:00 PM UTC

Financial Ratios

Market Cap1.29 Bn

P/E21.75

P/S1.22

Div. Yield0.00

ROIC (Qtr)0.00

Revenue Growth (1y) (Qtr)11.16

Add ratio to table…

About

ProAssurance Corporation is a holding company for property and casualty insurance companies operating primarily in the United States. The firm provides specialty property and casualty insurance, including medical professional liability and medical technology liability coverage, as well as workers compensation insurance. Through its subsidiaries it underwrites policies for healthcare providers, medical technology and life sciences companies, and employers across multiple states.

ProAssurance generates revenue mainly from insurance premiums written across its business lines. In 2025 net premiums written totaled $0.9 billion, derived from specialty P&C, workers compensation and segregated portfolio cell reinsurance activities. Additional income comes from investment returns and fees associated with agency and reinsurance operations.

The company operates through the following segments: Specialty P&C, Workers' Compensation Insurance, Segregated Portfolio Cell Reinsurance, and Corporate.

• Specialty P&C: This segment provides medical professional liability insurance to healthcare providers and institutions and medical technology liability insurance to medical device, pharmaceutical and life sciences companies, including coverage for products in commercial use and clinical trials.

• Workers' Compensation Insurance: This segment offers workers compensation policies to employers, primarily those with 1,000 employees or less, and provides alternative market solutions through segregated portfolio cells and unaffiliated captives.

• Segregated Portfolio Cell Reinsurance: This segment includes the underwriting and investment results of segregated portfolio cells at Inova Re and Eastern Re, which assume workers compensation and medical professional liability risks from the other insurance segments.

• Corporate: This segment manages the company's investment portfolio, provides administrative services to insurance subsidiaries, and handles corporate expenses, interest expense and tax items.

ProAssurance holds a competitive position in the specialty insurance market through its focus on healthcare and medical technology risks, strong claims management capabilities and a multistate presence. The company competes with large national insurers, regional carriers and niche providers, but differentiates itself with specialized underwriting expertise, a breadth of alternative risk solutions and a reputation for reliable service. Its size, financial strength and long term relationships with distributors support its ability to maintain underwriting discipline and pursue profitable opportunities.

ProAssurance serves healthcare providers such as hospitals, surgery centers and long term care facilities, medical technology and life sciences firms engaged in device manufacturing, pharmaceuticals and biologics, and employers seeking workers compensation coverage across its core states. The company also works with independent agents and brokers who distribute its products to these end users.

Investment Thesis

▲ Bull case

ProAssurance Corporation stands to benefit significantly from the pending merger with The Doctors Company, a transaction that has already cleared key regulatory hurdles in multiple states including Alabama, DC, Illinois, Missouri, Texas, and Vermont, received early termination of the Hart-Scott-Rodino waiting period by the FTC in July 2025, and secured overwhelming shareholder approval in June 2025. Management’s continued confidence in closing the deal by June 30, 2026, despite pending reviews in California and Pennsylvania, signals strong underlying momentum and reduces execution risk. The combined entity would create a dominant force in medical professional liability insurance with enhanced scale, broader product capabilities, and improved risk diversification across geographies and lines of business—factors that are not yet fully priced into the stock given the market’s focus on near-term premium declines. The merger’s potential to drive cost synergies, cross-selling opportunities, and stronger underwriting discipline represents a material, underappreciated catalyst for long-term value creation that extends beyond the current quarterly volatility in premiums and earnings.
Despite a 5.5% year-over-year decline in gross premiums written to $286.986 million in Q1 FY26, ProAssurance demonstrated meaningful improvement in underwriting profitability, with the net loss ratio improving to 77.9% from 80.4% in the prior year period and the combined ratio declining to 110.4% from 115.6%. This was driven by an 8.3% reduction in net losses and loss adjustment expenses to $174.194 million and a 12.8% drop in underwriting, policy acquisition, and operating expenses to $72.529 million—indicating disciplined risk selection and expense management even amid a soft premium environment. The Non-GAAP operating income surged 86.7% to $12.719 million, or $0.25 per diluted share, reflecting the tangible benefits of prior underwriting actions and reserve releases, which the market may be overlooking due to its fixation on top-line contraction. These trends suggest the company is effectively navigating a competitive pricing cycle while building a more resilient and profitable underwriting foundation, positioning it for margin expansion when market conditions stabilize or improve.
The Segregated Portfolio Cell Reinsurance segment delivered exceptional performance in Q1 FY26, with segment results jumping to $484 thousand from $182 thousand in the prior year—a 165.9% increase—driven by a 29.9% reduction in net losses and loss adjustment expenses to $5.299 million and a significant improvement in the net loss ratio to 49.3% from 65.8%. This outcome was bolstered by favorable prior accident years’ reserve development contributing (12.3) percentage points to the net loss ratio, compared to (3.0) points in the prior year, indicating stronger-than-expected runoff results. Though representing a smaller portion of the overall business, this segment’s strength highlights ProAssurance’s ability to generate alpha from specialized reinsurance structures and suggests underappreciated earnings potential from its alternative capital and specialty reinsurance platforms, which could become more meaningful contributors to consolidated profitability as the core medical professional liability business stabilizes.

ProAssurance Corporation stands to benefit significantly from the pending merger with The Doctors Company, a transaction that has already cleared key regulatory hurdles in multiple states including Alabama, DC, Illinois, Missouri, Texas, and Vermont, received early termination of the Hart-Scott-Rodino waiting period by the FTC in July 2025, and secured overwhelming shareholder approval in June 2025. Management’s continued confidence in closing the deal by June 30, 2026, despite pending reviews in California and Pennsylvania, signals strong underlying momentum and reduces execution risk. The combined entity would create a dominant force in medical professional liability insurance with enhanced scale, broader product capabilities, and improved risk diversification across geographies and lines of business—factors that are not yet fully priced into the stock given the market’s focus on near-term premium declines. The merger’s potential to drive cost synergies, cross-selling opportunities, and stronger underwriting discipline represents a material, underappreciated catalyst for long-term value creation that extends beyond the current quarterly volatility in premiums and earnings.
Despite a 5.5% year-over-year decline in gross premiums written to $286.986 million in Q1 FY26, ProAssurance demonstrated meaningful improvement in underwriting profitability, with the net loss ratio improving to 77.9% from 80.4% in the prior year period and the combined ratio declining to 110.4% from 115.6%. This was driven by an 8.3% reduction in net losses and loss adjustment expenses to $174.194 million and a 12.8% drop in underwriting, policy acquisition, and operating expenses to $72.529 million—indicating disciplined risk selection and expense management even amid a soft premium environment. The Non-GAAP operating income surged 86.7% to $12.719 million, or $0.25 per diluted share, reflecting the tangible benefits of prior underwriting actions and reserve releases, which the market may be overlooking due to its fixation on top-line contraction. These trends suggest the company is effectively navigating a competitive pricing cycle while building a more resilient and profitable underwriting foundation, positioning it for margin expansion when market conditions stabilize or improve.
The Segregated Portfolio Cell Reinsurance segment delivered exceptional performance in Q1 FY26, with segment results jumping to $484 thousand from $182 thousand in the prior year—a 165.9% increase—driven by a 29.9% reduction in net losses and loss adjustment expenses to $5.299 million and a significant improvement in the net loss ratio to 49.3% from 65.8%. This outcome was bolstered by favorable prior accident years’ reserve development contributing (12.3) percentage points to the net loss ratio, compared to (3.0) points in the prior year, indicating stronger-than-expected runoff results. Though representing a smaller portion of the overall business, this segment’s strength highlights ProAssurance’s ability to generate alpha from specialized reinsurance structures and suggests underappreciated earnings potential from its alternative capital and specialty reinsurance platforms, which could become more meaningful contributors to consolidated profitability as the core medical professional liability business stabilizes.

▼ Bear case

ProAssurance Corporation faces persistent top-line pressure, with gross premiums written declining 5.5% year-over-year to $286.986 million in Q1 FY26 and net premiums earned falling 5.4% to $223.505 million, reflecting ongoing challenges in retaining and growing business in its core medical professional liability and workers’ compensation lines. This decline is not merely a temporary soft market phenomenon but may signal deeper structural issues, including increased competition, pricing pressure from alternative capital providers, and potential deterioration in relationships with healthcare providers as consolidation in the provider sector reduces the number of independent purchasers of malpractice insurance. The company’s reliance on renewals and retention in a contracting addressable market raises concerns about its ability to grow organically without relying on costly acquisitions or assuming excessive risk to maintain volume—factors that could constrain long-term intrinsic value creation regardless of the merger’s outcome.
The Workers’ Compensation Insurance segment continued to deteriorate in Q1 FY26, with segment results worsening to a loss of $5.358 million from $3.842 million in the prior year period—a 39.5% decline in performance—driven by a 3.8% increase in net losses and loss adjustment expenses to $31.309 million and a rise in the current accident year net loss ratio to 77.0% from 75.0%. This trend contrasts sharply with improvements in the Specialty P&C segment and suggests that ProAssurance’s eastern U.S. workers’ compensation book may be experiencing worsening loss frequency or severity, possibly due to changing workplace dynamics, medical inflation, or inadequate rate adequacy. The segment’s persistent underperformance raises questions about the company’s underwriting discipline in this line and its ability to achieve profitable growth outside its traditional medical liability focus, especially as regulatory and medical cost trends remain unfavorable in key eastern states.
While ProAssurance highlights progress toward closing the merger with The Doctors Company by June 30, 2026, the indefinite delay in regulatory approval from California and Pennsylvania—two of the largest and most complex insurance markets—creates substantial execution risk. The timing of these reviews is explicitly described as “uncertain and outside our control,” and any further delay or potential conditioning of approval (such as divestitures or heightened oversight) could undermine the expected synergies, increase integration costs, or even jeopardize the deal’s economic rationale. Furthermore, the market may be underestimating the integration complexity of combining two large, culturally distinct insurers with overlapping operations, legacy systems, and differing risk appetites—factors that could erode expected benefits and distract management from core underwriting excellence during a critical period of industry softness.

ProAssurance Corporation faces persistent top-line pressure, with gross premiums written declining 5.5% year-over-year to $286.986 million in Q1 FY26 and net premiums earned falling 5.4% to $223.505 million, reflecting ongoing challenges in retaining and growing business in its core medical professional liability and workers’ compensation lines. This decline is not merely a temporary soft market phenomenon but may signal deeper structural issues, including increased competition, pricing pressure from alternative capital providers, and potential deterioration in relationships with healthcare providers as consolidation in the provider sector reduces the number of independent purchasers of malpractice insurance. The company’s reliance on renewals and retention in a contracting addressable market raises concerns about its ability to grow organically without relying on costly acquisitions or assuming excessive risk to maintain volume—factors that could constrain long-term intrinsic value creation regardless of the merger’s outcome.
The Workers’ Compensation Insurance segment continued to deteriorate in Q1 FY26, with segment results worsening to a loss of $5.358 million from $3.842 million in the prior year period—a 39.5% decline in performance—driven by a 3.8% increase in net losses and loss adjustment expenses to $31.309 million and a rise in the current accident year net loss ratio to 77.0% from 75.0%. This trend contrasts sharply with improvements in the Specialty P&C segment and suggests that ProAssurance’s eastern U.S. workers’ compensation book may be experiencing worsening loss frequency or severity, possibly due to changing workplace dynamics, medical inflation, or inadequate rate adequacy. The segment’s persistent underperformance raises questions about the company’s underwriting discipline in this line and its ability to achieve profitable growth outside its traditional medical liability focus, especially as regulatory and medical cost trends remain unfavorable in key eastern states.
While ProAssurance highlights progress toward closing the merger with The Doctors Company by June 30, 2026, the indefinite delay in regulatory approval from California and Pennsylvania—two of the largest and most complex insurance markets—creates substantial execution risk. The timing of these reviews is explicitly described as “uncertain and outside our control,” and any further delay or potential conditioning of approval (such as divestitures or heightened oversight) could undermine the expected synergies, increase integration costs, or even jeopardize the deal’s economic rationale. Furthermore, the market may be underestimating the integration complexity of combining two large, culturally distinct insurers with overlapping operations, legacy systems, and differing risk appetites—factors that could erode expected benefits and distract management from core underwriting excellence during a critical period of industry softness.

Segments Breakdown of Revenue (2023)

Peer Comparison

Companies in the Insurance - Property & Casualty

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	MKL	Markel Group Inc.	7,105.55 Bn	4,049.14	596.80	-
2	PGR	Progressive Corp/Oh/	131.92 Bn	11.41	1.53	-
3	CB	Chubb Ltd	78.78 Bn	6.78	1.23	1.93 Bn
4	CINF	Cincinnati Financial Corp	74.32 Bn	23.75	6.52	0.86 Bn
5	TRV	Travelers Companies, Inc.	72.03 Bn	9.47	1.41	-
6	ALL	Allstate Corp	63.08 Bn	5.25	0.93	-
7	FRFHF	Fairfax Financial Holdings Ltd/ Can	34.53 Bn	10.52	-	-
8	L	Loews Corp	23.53 Bn	13.57	1.60	8.93 Bn

Research Tools

Developers

About

Investment Thesis

Segments Breakdown of Revenue (2023)

Segments Breakdown of Revenue (2023)

Peer Comparison

Research Tools

Developers

About

Investment Thesis

Segments Breakdown of Revenue (2023)

Segments Breakdown of Revenue (2023)

Peer Comparison

Create an account

Sign In

Reset Password